Psmg2 Inhibitors
Chemical inhibitors of Psmg2 can impede its function through various mechanisms that disrupt different cellular processes. Oligomycin A targets mitochondrial ATP synthase, creating an energy-deficient state that ultimately affects energy-dependent proteins such as Psmg2. Similarly, compounds like Bortezomib and MG-132 inhibit the ubiquitin-proteasome pathway, leading to an accumulation of proteins that require degradation. This accumulation can overwhelm the protein quality control systems in which Psmg2 functions, indirectly inhibiting its activity. Cycloheximide, on the other hand, inhibits protein synthesis, thereby reducing the pool of new proteins that would typically require the chaperoning services of Psmg2, thereby reducing its functional load.
Furthermore, Tunicamycin inhibits N-linked glycosylation, which can affect the folding and function of substrates that Psmg2 would normally act upon. Eeyarestatin I disrupts ER-associated degradation pathways, which also impacts protein quality control mechanisms involving Psmg2. Withaferin A and Epoxomicin, both proteasome inhibitors, lead to a similar outcome as Bortezomib and MG-132 by preventing the degradation of ubiquitinated proteins, thereby causing a backlog that indirectly impedes Psmg2's role. Additionally, Piperlongumine increases reactive oxygen species within cells, leading to oxidative stress conditions that can inhibit Psmg2 activity. Puromycin causes premature chain termination during protein translation, leading to a decreased availability of nascent proteins for Psmg2 to act upon. Lastly, Lactacystin and Salubrinal inhibit the proteasome and eIF2α dephosphorylation, respectively, both of which lead to reduced protein synthesis or accumulation of polyubiquitinated proteins, further inhibiting Psmg2's function within the cell's protein quality control systems.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Oligomycin A | 579-13-5 | sc-201551 sc-201551A sc-201551B sc-201551C sc-201551D | 5 mg 25 mg 100 mg 500 mg 1 g | $179.00 $612.00 $1203.00 $5202.00 $9364.00 | 26 | |
Oligomycin A inhibits mitochondrial ATP synthase, which creates an energy deficiency in the cell. Psmg2 activity is energy-dependent; therefore, energy depletion can lead to functional inhibition of Psmg2. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded proteins, triggering the unfolded protein response (UPR) and potentially overloading the protein quality control system, within which Psmg2 operates, thus inhibiting its function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is an inhibitor of the ubiquitin-proteasome pathway. By inhibiting proteasomal activity, MG-132 can cause a backup of proteins needing degradation, indirectly inhibiting Psmg2 by overwhelming the protein quality control system. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits protein synthesis by interfering with the translocation step in protein elongation. While not affecting Psmg2 directly, the reduction in new protein synthesis can reduce the substrate availability for Psmg2, thus impeding its function. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation. Psmg2, as a chaperone involved in protein folding, may require glycosylation for its substrate proteins' proper folding and function; inhibition of this process can indirectly inhibit Psmg2. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
Eeyarestatin I disrupts ER-associated degradation (ERAD) by inhibiting the p97 ATPase and the deubiquitinase activity of USP14. This can lead to dysfunction in the protein degradation pathway, indirectly inhibiting the function of Psmg2 involved in protein quality control. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A is known to disrupt the protein-protein interactions necessary for proper proteasome function, potentially affecting Psmg2's associated pathways and indirectly inhibiting its activity due to proteasome dysfunction. | ||||||
Piperlongumine | 20069-09-4 | sc-364128 | 10 mg | $107.00 | ||
Piperlongumine increases the levels of reactive oxygen species (ROS) within cells, leading to oxidative stress. Psmg2 function depends on a controlled cellular redox state, and the disruption can inhibit its activity. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $166.00 $322.00 | 436 | |
Puromycin causes premature chain termination during translation. By prematurely terminating protein synthesis, puromycin can indirectly inhibit Psmg2 by reducing the pool of nascent proteins that require the chaperoning activity of Psmg2. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor. By inhibiting proteasomal degradation, it can cause an accumulation of proteins that require refolding, indirectly inhibiting Psmg2 due to increased demand on the protein folding machinery. | ||||||